From Lab Table to Clinic - GMP in Biopharmaceutical Development (2)
This course gives answers to the question of which regulatory aspects are important throughout the product development cycle. What are the GMP requirements at the various stages of product development (research, animal studies, clinical phase I, II & III)
- 2 days
- Course fee
- € 1495 (excl. VAT)
This is a modular designed training wherein various GMP issues that are important for the development process of biopharmaceutical products are dealt with.
This training also discusses the different regulatory standards required during the various phases of the process (development, animal research, clinical phases I, II and III).
The training "From lab table to clinic" is presented in 2 modules:
- Module 1: GMP in an R&D environment (1 day). You can read more about the first module of the course here.
- Module 2: From lab table to clinic (2 days).
Module 2 - 'From lab table to clinic'
The development of medicines up until the clinical phase is paved with all sorts of challenges. These include the scaling up/migration of the production process (from the lab table to a GMP production environment) to the setting up of the correct analytical methods in order to obtain stability data.
These activities should take place at the stage where you have limited knowledge of the product, the production processes and the analytical methods and where it is not clear how to apply the GMP standards required. Furthermore it is also not clear at this stage which regulatory requirements should apply to which phase of the production process.
This module will provide more insight into the following subjects:
The life-cycle / development process of a pharmaceutical product
- What does the life-cycle of a medicine look like?
- What steps does a medicine have to undergo from the lab table up until the finished product is approved and brought to the market?
- What guidelines must I follow? In which phase of the development process?
Production, characterization and management of Cell Banks and Seed Lots
- In which phase must I generate and characterize a Cell Bank and Seed Lot?
- What does GMP have to do with the generation and characterization of Cell Banks and Seed Lots?
- How many Cell Banks / Seed Lots should I generate?
- How to apply risk management during the development process of medicines
- What risk management techniques are available?
Process for development and production
- Do I have to apply full blown GMP from day one or can I phase it in?
- How can I distinguish between the various phases?
Process for validation
- Which processes have to be validated and in which phase of the development process?
- What does the validation of the production processes actually mean?
Test methods and test validation
- When must I validate the analytical methods?
- What does the validation of the analytical methods actually mean?
- What stability data is necessary for clinical phase I?
- How can I obtain stability data for the registration file?
- What tests must be carried out on a product?
- How do I prepare the correct specifications?
- Would I need to have the same kind of specifications for material used in clinical phase I as I also would need for the registered product?
Investigational Medicinal Product (IMP): production, testing, release and transportation
- What are the critical considerations for the manufacture, analysis and shipment of an Investigational Medicinal Product (IMP)?
- What would be expected of you if you made changes to the production process, the analytical methods, the formulation and/or the reference standard during the development process?
- Knowing and understanding the diverse GMP areas that would be applicable during the development of new medicines.
- Gaining practical and simple reference points to enable start up and implementation of these GMP areas.
- Turning acquired knowledge directly into practical applications by alternating lectures with workshops
- Staff who work in or who are outsourced into an R&D environment.
- Staff who just want to know more about GMP.
- Staff who work in a pharmaceutical company but have not (yet) worked under GMP conditions.
Jolanda Muurman (Muurman QA & QP Services)
Wilma Meijs (Wilma Meijs Farmaceutisch Advies BV)
The life-cycle of a pharmaceutical product
Carry out a risk assessment process
Establish a protocol to validate a process
Wed 30 Oct
Thu 31 Oct
- Wed 30 Oct
Keep me up to date
Leave your e-mail address to receive a notification when new training dates become available.
Your e-mail address will not be used for other purposes.
Need help? Have a question or a suggestion maybe?
Drop us a line below or call us on
+31 (0) 88 283 01 00.